SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
The predicated demise of racemic new molecular entities is an exaggeration
2 references·0 citing·7 second hop
The predicated demise of racemic new molecular entities is an exaggeration (2012)The predicated demise of racemic new mole…2011 FDA drug approvals (2012)2011 FDA drug approvalsThe strategy of enantiomer patents of drugs (2010)The strategy of enantiomer pa…Intellectual property and chirality of drugs (1999)Secondary Patenting Of Branded Pharmaceuticals: A Case Study Of How Patents On Two HIV Drugs Could Be Extended For Decades (2012)“New Drug” Designations for New Therapeutic Entities: New Active Substance, New Chemical Entity, New Biological Entity, New Molecular Entity (2014)Chiral Switch: Between Therapeutical Benefit and Marketing Strategy (2022)Are new models needed to optimize the utilization of new medicines to sustain healthcare systems? (2014)Two Decades of Publishing Excellence in Pharmaceutical Biotechnology (2014)Benchmarking R&D success rates of leading pharmaceutical companies: an empirical analysis of FDA approvals (2006–2022) (2025)
this work references cited by second hop

References

  • 20122011 FDA drug approvals156 cited
  • 2010The strategy of enantiomer patents of drugs61 cited

Cited by

No citing works inside the corpus for this window.

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work